Page 116 - Haematologica July

M. Bellei et al.
A
B
Table 2. Details of treatment and events for the refractory/relapsed patients (n=633).
Parameter Refractory (n=436)
Figure 2. Survival after relapse (SAR). (A) SAR curve of 633 refractory/relapsed patients. (B) SAR by status: refractory versus relapse. Refractory patients are those with primary refractoriness.
Relapsed All (n=197) (n=633)
Unsatisfactory PR Refractory(<PR)
Timing of events
Refractory
Early relapse (≤ 12 months) Late relapse (>12 months)
HCT as Salvage
HCT, yes
No HCT (eligible for HCT)
No HCT (CR/PR not eligible for HCT) No HCT (<PR not eligible for HCT) No HCT (whichever the reason)
137 31 299 69
436 69 - - - -
- - - -
- - 125 20 72 11
N%N%N%
Type of event
RelapseafterCR - - 170 86 RelapseafterPR - - 27 14
170 27 27 4 137 22 299 47
436 69 125 20 72 11
99 16
534 84
1194
42 9 57 29 - - 124 63 125 29 16 8
269 62 - - 394 91 140 71
CR: complete remission; PR: partial remission; Unsatisfactory PR: PR requiring immediate treatment after initial therapy; HCT: hematopoietic cell transplantation.
haematologica | 2018; 103(7)